Assembly Biosciences’ (ASMB) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a research report sent to investors on Friday morning,Benzinga reports.

Separately, Jefferies Financial Group raised Assembly Biosciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $2.00 to $35.00 in a research note on Friday, September 20th.

Assembly Biosciences Price Performance

Assembly Biosciences stock opened at $15.16 on Friday. Assembly Biosciences has a 52 week low of $9.12 and a 52 week high of $19.93. The stock has a fifty day moving average of $16.05 and a 200-day moving average of $15.59.

Insiders Place Their Bets

In other news, major shareholder Alexander Schornstein purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, October 8th. The shares were purchased at an average cost of $14.58 per share, with a total value of $145,800.00. Following the completion of the purchase, the insider now owns 703,113 shares of the company’s stock, valued at $10,251,387.54. This trade represents a 1.44 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Over the last quarter, insiders have sold 394 shares of company stock valued at $5,894. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Armistice Capital LLC bought a new stake in Assembly Biosciences during the 2nd quarter worth approximately $6,421,000. Renaissance Technologies LLC lifted its holdings in shares of Assembly Biosciences by 39.2% during the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 15,451 shares during the period. FMR LLC grew its stake in shares of Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 3,635 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 7,690 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 3,442 shares during the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.